Monsanto-Syngenta Deal Could Force Major Ag Reshuffle

A merger of agrochemicals giants Monsanto and Syngenta would force their competitors to reconsider their own strategies and review cross-licensing deals, Liam Condon, CEO of Bayer CropScience, told the news agency Bloomberg.
If Monsanto ups its $45 billion bid and wins the hearts and minds of Syngenta shareholders, "it would definitely force a review of how everybody is going to react," Condon said.
“There's only six research and development based players in this industry so if the two biggest were to go together, inevitably it would force others to review their strategies,” he added.
Both Bayer and German rival BASF have been named as candidates to buy Syngenta's seed business, which Monsanto has acknowledged it would sell to allay antitrust concerns.
Bloomberg cites people familiar with the matter as saying Monsanto pitched this idea to Bayer last year.
With sales of $10.4 billion, Bayer is the second largest producer of chemical crop protectants – a market Monsanto is keen to enter to balance a portfolio currently top-heavy with seed products.
The Leverkusen group has a clear view on how to respond in the event Monsanto proceeds with its takeover plan, Condon told the news agency. The CropScience chief noted also that, along with divesting overlapping herbicide assets, combining Monsanto and Syngenta also would mean unraveling an intricate web of agreements in R&D licensing and production.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.